Ranok Expands Clinical Testing of CHAMP® BRD4 Protein Degrader RNK05047
11 Mar 2024 //
BUSINESSWIRE
Ranok begins subject dosing in Phase I/II cancer trial
25 Aug 2022 //
CLINICALTRIALSARENA
Ranok Announces Initiation of Dosing in a Phase 1/2 Clinical Trial of RNK05047
24 Aug 2022 //
BUSINESSWIRE
FDA Clears Ranok`s First-in-Human Trial of RNK05047 in Cancers & Lymphomas
24 Jan 2022 //
BUSINESSWIRE
Ranok Therapeutics Announces Agreement with Pfizer on Targeted Degradation
29 Nov 2021 //
BUSINESSWIRE